GILD Gilead Sciences, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
GILD Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - General
Current Price
Live
$124.91
Analyst Target
$134.19
+7.4%
Upside
52W High
$128.7
52W Low
$91.84
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 17, 2026
Market cap
$154.99B
P/E
19.34
ROE
40.7%
Profit margin
27.9%
Debt/Equity
1.16
Dividend yield
2.61%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Gilead Sciences has a weak Piotroski F-Score of 4/9, indicating stable but not strong financial health, and lacks an Altman Z-Score, limiting distress risk assessment. Despite solid profitability metrics—ROE of 40.71%, gross margin of 78.72%, and strong earnings growth—the stock trades above its Graham Number ($50.21) at $124.91, supported by a forward P/E of 14.24 and analyst target of $134.19. However, bearish insider activity, weak technical trend (10/100), and declining recent earnings surprises weigh on momentum. The company remains cash generative with a sustainable dividend, but growth is modest relative to peers.
Key Strengths
Exceptional profitability with ROE of 40.71% and operating margin of 45.23%
Strong earnings growth: YoY EPS up 22.3%, Q/Q EPS up 58.3%
Beating earnings estimates in 3 of last 4 quarters with strong historical surprise record
Solid dividend yield of 2.61% with a reasonable 48.61% payout ratio
Trading below analyst consensus target price of $134.19, implying 7.4% upside
Key Risks
Low Piotroski F-Score of 4/9 suggests suboptimal financial stability and operational efficiency
Bearish insider sentiment: 11 sell transactions totaling $16.56M, no buys in last 6 months
Technical trend is deeply bearish at 10/100, signaling weak price momentum
Price/Book of 7.20 and Price/Sales of 5.33 indicate rich valuation relative to book and sales
Revenue growth is low at 3.00% YoY, lagging sector average of 9.80%
AI Fair Value Estimate
Based on comprehensive analysis
$134.19
+7.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
64
Strong
58
70
66
52
76
AI Verdict
Neutral with upside potential if growth sustains
Key drivers: Strong earnings growth and profitability, Low Piotroski score and bearish technicals, Rich valuation multiples, Bullish analyst target vs current price, Bearish insider activity
Confidence
75%
Value
58/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 14.24 is reasonable for a stable pharma player
- Trading below analyst target of $134.19
Watchpoints
- Current price ($124.91) is more than 2.5x the Graham Number ($50.21)
- High Price/Book (7.20) and Price/Sales (5.33) vs sector averages
Future
70/100
Ref Growth rates
Positives
- Strong YoY and Q/Q earnings growth (22.3%, 58.3%)
- Forward P/E of 14.24 implies reasonable growth expectations
Watchpoints
- Revenue growth of 3.00% YoY is below sector average of 9.80%
- PEG Ratio is unavailable, limiting growth-adjusted valuation
Past
66/100
Ref Historical trends
Positives
- History of beating earnings estimates, including +30.5% and +48.7% surprises
- 5-year price return of +125.7% outperforms most peers
Watchpoints
- Earnings surprises have trended downward recently
- One major negative surprise (-56.6%) in early 2022 raises volatility concern
Health
52/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio (1.45) and quick ratio (1.10) indicate adequate liquidity
- Debt/Equity of 1.16 is manageable for the sector
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Altman Z-Score is missing, creating uncertainty in bankruptcy risk
Dividend
76/100
Ref Yield, Payout
Positives
- Dividend yield of 2.61% is above S&P 500 average
- Payout ratio of 48.61% is sustainable with room for growth
Watchpoints
- Dividend Strength score is only 50/100, suggesting moderate reliability
- No 5-year average yield provided for trend analysis
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$124.91
Analyst Target
$134.19
Upside/Downside
+7.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GILD and closest competitors.
Updated 2026-01-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences, Inc.
Primary
|
+125.7% | +62.5% | +40.1% | +17.0% | +2.9% | +3.1% |
|
PFE
Pfizer Inc.
Peer
|
-10.9% | -33.8% | +3.8% | +8.5% | +2.4% | +0.7% |
|
DHR
Danaher Corporation
Peer
|
+15.2% | -1.7% | -1.8% | +24.6% | +6.2% | -1.0% |
|
SYK
Stryker Corporation
Peer
|
+58.2% | +46.1% | -3.8% | -6.1% | +3.4% | -1.0% |
|
BSX
Boston Scientific Corporation
Peer
|
+151.5% | +101.8% | -9.0% | -12.8% | -3.8% | +5.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
19.34
Forward P/E
14.24
PEG Ratio
N/A
P/B Ratio
7.2
P/S Ratio
5.33
EV/Revenue
5.89
EV/EBITDA
12.12
Market Cap
$154.99B
Profitability
Profit margins and return metrics
Profit Margin
27.88%
Operating Margin
45.23%
Gross Margin
78.72%
ROE
40.71%
ROA
12.57%
Growth
Revenue and earnings growth rates
Revenue Growth
+3.0%
Earnings Growth
+143.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+143.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.16
Moderate
Current Ratio
1.45
Good
Quick Ratio
1.1
Good
Cash/Share
$6.84
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-10
$N/A
2025-10-30
$2.47
+15.7% surprise
2025-08-07
$1.56
+5.1% surprise
2025-04-24
$1.81
+1.9% surprise
Healthcare Sector Comparison
Comparing GILD against 147 companies in the Healthcare sector
(9 bullish, 56 neutral, 82 bearish)
P/E Ratio
19.34
This Stock
vs
164.76
Sector Avg
-88.3%
(Discount)
Return on Equity (ROE)
40.71%
This Stock
vs
-53.48%
Sector Avg
-176.1%
(Below Avg)
Profit Margin
27.88%
This Stock
vs
-20.64%
Sector Avg
-235.1%
(Weaker)
Debt to Equity
1.16
This Stock
vs
6.19
Sector Avg
-81.2%
(Less Debt)
Revenue Growth
3.0%
This Stock
vs
137.13%
Sector Avg
-97.8%
(Slower)
Current Ratio
1.45
This Stock
vs
3.37
Sector Avg
-56.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $154.99B | 19.34 | 40.7% | 27.9% | $124.91 | |
|
PFE
Pfizer Inc.
|
NEUTRAL | $145.84B | 14.91 | 10.6% | 15.7% | $25.65 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $168.98B | 48.46 | 6.8% | 14.4% | $235.99 | |
|
SYK
Stryker Corporation
|
BEARISH | $139.12B | 47.8 | 14.0% | 12.1% | $363.78 | |
|
BSX
Boston Scientific Corporation
|
NEUTRAL | $137.19B | 48.69 | 12.5% | 14.4% | $92.51 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | BERGER DIETMAR P. | Officer | Stock Award | 16,326 | - |
| 2025-12-29 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | 10,000 | $1,248,272 |
| 2025-12-15 | MERCIER JOHANNA | Officer | Sale | 3,000 | $366,000 |
| 2025-12-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale | 3,000 | $366,000 |
| 2025-12-10 | MERCIER JOHANNA | Officer | Stock Award | 3,842 | - |
| 2025-12-10 | O'DAY DANIEL PATRICK | Chief Executive Officer | Stock Award | 10,426 | - |
| 2025-12-10 | DICKINSON ANDREW D | Chief Financial Officer | Stock Award | 3,693 | - |
| 2025-11-28 | BLUESTONE JEFFREY | Director | Option Exercise | 5,000 | $324,600 |
| 2025-11-28 | KRAMER KELLY A | Director | Option Exercise | 5,611 | $454,491 |
| 2025-11-28 | BLUESTONE JEFFREY | Director | Sale | 5,000 | $625,400 |
| 2025-11-28 | KRAMER KELLY A | Director | Sale | 5,611 | $713,186 |
| 2025-11-28 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | 10,000 | $1,265,444 |
| 2025-11-17 | MERCIER JOHANNA | Officer | Option Exercise | 25,000 | $1,666,000 |
| 2025-11-17 | MERCIER JOHANNA | Officer | Sale | 28,000 | $3,524,173 |
| 2025-11-17 | DICKINSON ANDREW D | Chief Financial Officer | Sale | 2,500 | $313,075 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
26 analysts
Morgan Stanley
2026-01-13
Overweight
Overweight
Citigroup
2026-01-07
Buy
Buy
Morgan Stanley
2025-12-12
Overweight
Overweight
Wells Fargo
2025-12-10
Overweight
Overweight
Needham
2025-11-13
Buy
Buy
Scotiabank
2025-11-13
Sector Outperform
Truist Securities
2025-11-03
Buy
Buy
Wells Fargo
2025-10-31
Overweight
Overweight
JP Morgan
2025-10-31
Overweight
Overweight
RBC Capital
2025-10-31
Sector Perform
Sector Perform
Past News Coverage
Recent headlines mentioning GILD from our newsroom.
Newest → oldest
No matching news yet.